



Press release  
Regulated information

## Omega Pharma issues retail bond on 5 and 7 years with a respective annual interest rate of 4.5% and 5.0%

Nazareth (Belgium) - 24 April 2012 (08.30 a.m. CET). Omega Pharma announces that it makes a public offer in Belgium and the Grand-Duchy of Luxembourg for a series of retail bonds for an expected total minimum amount of 25 million euro each and a combined expected total minimum amount of 100 million euro. The fixed rate for the bonds due 2017 is 4.500% and for the bonds due 2019 this is 5.000%.

The denomination of the bonds shall be 1,000 euro. The subscription period runs from 26 April 2012 until and including 16 May 2012, subject to early closing. The issue date is 23 May 2012. Application has been made for the bonds to be listed on the Luxembourg Stock Exchange.

The bonds are intended to finance part of the acquisition by Omega Pharma of an important portfolio of European OTC brands from GSK.

ING Belgium, KBC Bank, Belfius Bank and BNP Paribas Fortis act as 'Joint Lead Managers' for this issue.

More information about this public offer can be found in the corresponding prospectus of 23 April 2012, approved by the *Commission de Surveillance du Secteur Financier* (Luxembourg), which is available at the Joint Lead Managers as well as on the company's website: [www.omega-pharma.be](http://www.omega-pharma.be).

Omega Pharma is an OTC healthcare company headquartered in Nazareth (Belgium) with operations in 35 countries across Europe and selected emerging markets. Its products are sold across an extensive network of pharmacies and related retail outlets.

(end)